BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  company  Roche  Registration  Limited  submitted  on  1  July  2002  an  application  for  Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Bonviva, 
through the centralised procedure. After agreement by the CPMP on 21 February 2002, this medicinal 
product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 
1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP and the evaluation teams were: 
Rapporteur:  Dr Mark Ainsworth 
Co-Rapporteur: 
Prof. Heribert Pittner 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 22 July 2002. 
The  Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on  2  October 
2002.  The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on  2 
October 2002. 
During  the  meeting  on  19-21  November  2002  the  CPMP  agreed  on  the  consolidated  list  of 
questions  to  be  sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the 
company on 21 November 2002. 
The company submitted the responses to the consolidated list of questions on 16 April 2003. 
The Rapporteur circulated the response assessment report on the company’s responses to the list 
of questions to all CPMP Members on 26 May 2003. 
During the CPMP meeting on 24-26 June 2003, the CPMP agreed on a list of outstanding issues 
to be addressed in writing by the applicant (Annex 5). 
The company submitted the responses to the CPMP consolidated List of Outstanding issues on 
25 July 2003 
During the meeting on 21-23 October 2003 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Bonviva (ibandronic acid) on 23 October 2003. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 23 February 2004. 
1/1 
EMEA 2004 
 
 
 
 
 
 
 
